Piers Ingram – Co-Founder & CEO, Hummingbird Bioscience
Dr Piers Ingram, PhD, co-founder, and CEO of Singapore-based biotech Hummingbird Bioscience, shares his motivation…
GBI
Last updated: 13.02.2014
Address: Suite 301, Building 2
169 Mengzi Road
Shanghai, 200032 P.R. China
Tel: +86(21) 53022951
Web: http://www.gbipharma.com/
Company description
Gbipharma.com is an information, business intelligence, and consulting company which has been servicing the pharmaceutical, biotechnology, and healthcare sectors, as well as investors and other financial and consulting service providers since 2002. We aim to provide a total information solution for companies within or intending to enter China’s market.
Gbipharma.com’s content and tools are targeted at individuals within marketing, business development, R&D, and operations functions up through top country and regional management levels. Our information products include the “China Pharmaceutical & Biotechnology Monthly”, the definitive English-language publication covering China’s pharma and healthcare sectors, and SOURCE, the ultimate (bilingual) information database service for pharmaceuticals in China.
GBI’s content has been created through rigorous primary and secondary research. Information is not easy to collect in China, and much misinformation exists. (Even publicly available data may be hard to compile, poorly organized, and non-standard, often rendering the information essentially unusable in its raw forms.) GBI’s analysts and managers have extensive experience in China’s pharmaceutical and healthcare sectors and are committed to creating meaningful, timely, and actionable information for their clients.
Products and services
Information Services, Consulting
Interviews
Chengbin Wu – CEO, EpimAb Biotherapeutics, China
Dr Chengbin Wu, founder and CEO of EpimAb Biotherapeutics, introduces their exciting and proprietary bispecific…
Related
China / Sinopharm Looks to mRNA Vaccines; Hong Kong Biotech Investment Continues to Boom; Another Big Manufacturing Investment for Lonza
The latest news from Chinese pharma and biotech, including news that state-owned Sinopharm is now developing its…
China / PhIRDA’s Song Ruilin on Strengthening Drug Supervision Capacity & Promoting Pharma Innovation
Song Ruilin, chairman of the China Pharmaceutical Innovation and Research Development Association (PhIRDA), picks…
China / CDE’s Drug Evaluation Report 2020: Part 1
The following is an overview from Accestra Consulting* of Part 1 of China’s Center for Drug Evaluation (CDE)’s…
China / Fosun Sales up 20%; MNC Price Manoeuvres Lead to Growth; Bayer Sees ‘Golden Age’ Ahead
The latest news from Chinese pharma, including Fosun Pharma’s 2021 interim results; how AstraZeneca, Bayer, Eli…
China / Striving for First-In-Class Drug Innovation with New Patent Law
In a comprehensive new piece, European Patent Attorney André Bourgouin and Adjunct Professor at CEIBS Eric…
China / Hong Chow Leaves Roche for Big New Role at Merck
In a big career move on a personal level and a sign of China’s continuing significance to global pharma, Hong…
China / Sinopharm Tops Brand Value Rankings; Simcere Splashes $565M on Alzheimer’s Drug; Innovent-Ascentage Tie-Up A Sign of Biotech Deals to Come?
The latest news from the Chinese pharmaceutical industry, including recent deals between domestic pharma giant…
China / Fosun-Kite Yescarta Approval Signals Beginning of CAR-T Era
A historic approval for Fosun-Kite’s CAR-T therapy Yescarta in China looks set to pave the way for further…
China / First CAR-T Approval; AZ & Bayer Take VBP Hit; Lonza Boosts Manufacturing Capacity
The latest news from Chinese pharma, including a historic first approval for Fosun Kite’s CAR-T therapy Yescarta;…
China / New Country President for MSD Amid Changes at HQ & Access Challenges
MSD, which has had a presence in China since 1990, recently appointed Belgian national Anna van Acker to lead its…
China / A New Era of Reform Transforming Regulatory Professionals
Writing in the June edition of DIA’s Global Forum magazine, Harbour BioMed’s Fang Zhou, in conversation…
Hong Kong / HKEX’s Aim to Become World’s #1 Biotech Listing Hub & Challenges for New CEO
With three years having passed since the Hong Kong Stock Exchange (HKEX)’s decision to allow pre-revenue biotechs…
